Jianeng Zhang, Huanhuan Zhang, Wenjing Zhou, Meiyan Jiang, Xianhua Lin
{"title":"Effect of myo-inositol supplementation in mixed ovarian response IVF cohort: a systematic review and meta-analysis.","authors":"Jianeng Zhang, Huanhuan Zhang, Wenjing Zhou, Meiyan Jiang, Xianhua Lin","doi":"10.3389/fendo.2025.1520362","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>There has been substantial research conducted recently on the effect of myo-inositol (MI) on human reproduction. However, it still remains ambiguous about the therapeutic efficacy of MI in infertile women undergoing <i>in vitro</i> fertilization embryo transfer (IVF-ET). This systematic review and meta-analysis was carried out to investigate the efficacy of MI on IVF outcomes.</p><p><strong>Methods: </strong>Literatures were searched in the PubMed, Web of Science, Cochrane Library, ScienceDirect and Wanfang databases. The methodological quality was assessed using the Cochrane Risk of Bias tool. Data were pooled using a random- or fixed-effects model according to study heterogeneity. The results are expressed as odds ratio (OR) or mean difference (MD) with 95% confidence intervals (CIs). Heterogeneity was measured by the I<sup>2</sup> statistic. The protocol was prospectively registered with PROSPERO (CRD42024582149).</p><p><strong>Results: </strong>Eleven eligible studies with 981 participants reported the IVF outcomes of the MI group versus the control group. The synthesis results showed that the metaphase II (MII) oocyte rate was higher in the MI group than in the control group (OR 1.55, 95% CI 1.04-2.31, <i>P</i>=0.03). For polycystic ovary syndrome (PCOS) women, as well as non-obese PCOS women, a statistically significant improvement in MII oocyte rate were assumed after taking MI (OR 1.97, 95% CI 1.20-3.25, <i>P</i><0.01; OR 1.92, 95% CI 1.09-3.37, <i>P</i>=0.02) while there is no statistically significant advancement showed in the poor ovary responder (POR) women(OR 0.97, 95% CI 0.35-2.68, <i>P</i>=0.95). The fertilization rate was higher in the MI group than in the control group (OR 1.62, 95% CI 1.21-2.16, <i>P</i><0.01), for PCOS, non-obese PCOS and POR women (OR 1.59, 95% CI 1.16-2.18, <i>P</i><0.01; OR 1.87, 95% CI 1.52-2.31, <i>P</i><0.01; OR 2.42, 95% CI 1.48-3.95, <i>P</i><0.01).</p><p><strong>Conclusions: </strong>Our results suggest that MI supplementation improves the MII oocyte rate and the fertilization rate. More high-grade evidence from prospective randomized studies is warranted.</p><p><strong>Systematic review registration: </strong>https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42024582149.</p>","PeriodicalId":12447,"journal":{"name":"Frontiers in Endocrinology","volume":"16 ","pages":"1520362"},"PeriodicalIF":3.9000,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11968372/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Endocrinology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fendo.2025.1520362","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: There has been substantial research conducted recently on the effect of myo-inositol (MI) on human reproduction. However, it still remains ambiguous about the therapeutic efficacy of MI in infertile women undergoing in vitro fertilization embryo transfer (IVF-ET). This systematic review and meta-analysis was carried out to investigate the efficacy of MI on IVF outcomes.
Methods: Literatures were searched in the PubMed, Web of Science, Cochrane Library, ScienceDirect and Wanfang databases. The methodological quality was assessed using the Cochrane Risk of Bias tool. Data were pooled using a random- or fixed-effects model according to study heterogeneity. The results are expressed as odds ratio (OR) or mean difference (MD) with 95% confidence intervals (CIs). Heterogeneity was measured by the I2 statistic. The protocol was prospectively registered with PROSPERO (CRD42024582149).
Results: Eleven eligible studies with 981 participants reported the IVF outcomes of the MI group versus the control group. The synthesis results showed that the metaphase II (MII) oocyte rate was higher in the MI group than in the control group (OR 1.55, 95% CI 1.04-2.31, P=0.03). For polycystic ovary syndrome (PCOS) women, as well as non-obese PCOS women, a statistically significant improvement in MII oocyte rate were assumed after taking MI (OR 1.97, 95% CI 1.20-3.25, P<0.01; OR 1.92, 95% CI 1.09-3.37, P=0.02) while there is no statistically significant advancement showed in the poor ovary responder (POR) women(OR 0.97, 95% CI 0.35-2.68, P=0.95). The fertilization rate was higher in the MI group than in the control group (OR 1.62, 95% CI 1.21-2.16, P<0.01), for PCOS, non-obese PCOS and POR women (OR 1.59, 95% CI 1.16-2.18, P<0.01; OR 1.87, 95% CI 1.52-2.31, P<0.01; OR 2.42, 95% CI 1.48-3.95, P<0.01).
Conclusions: Our results suggest that MI supplementation improves the MII oocyte rate and the fertilization rate. More high-grade evidence from prospective randomized studies is warranted.
目的：近年来，关于肌醇（MI）对人类生殖的影响已有大量研究。然而，对于接受体外受精胚胎移植（IVF-ET）的不孕妇女而言，肌醇的疗效仍不明确。本系统综述和荟萃分析旨在研究 MI 对试管婴儿结果的疗效：方法：在PubMed、Web of Science、Cochrane Library、ScienceDirect和万方数据库中检索文献。使用 Cochrane 偏倚风险工具对方法学质量进行评估。根据研究的异质性，采用随机或固定效应模型对数据进行汇总。结果以几率比（OR）或平均差（MD）表示，并附有 95% 的置信区间（CI）。异质性用 I2 统计量来衡量。研究方案已在 PROSPERO（CRD42024582149）进行了前瞻性注册：结果：11 项符合条件的研究共 981 名参与者报告了 MI 组与对照组的 IVF 结果。综合结果显示，MI 组的 II 期（MII）卵母细胞率高于对照组（OR 1.55，95% CI 1.04-2.31，P=0.03）。对于多囊卵巢综合征（PCOS）妇女和非肥胖 PCOS 妇女，服用 MI 后，MII 卵母细胞率在统计学上有显著提高（OR 1.97，95% CI 1.20-3.25，PP=0.02），而卵巢反应不良（POR）妇女的 MII 卵母细胞率在统计学上没有显著提高（OR 0.97，95% CI 0.35-2.68，P=0.95）。MI组的受精率高于对照组（OR 1.62，95% CI 1.21-2.16，P=0.95）：我们的研究结果表明，补充 MI 可提高 MII 卵母细胞率和受精率。系统综述注册：https://www.crd.york.ac.uk/PROSPERO/，标识符为 CRD42024582149。
期刊介绍：
Frontiers in Endocrinology is a field journal of the "Frontiers in" journal series.
In today’s world, endocrinology is becoming increasingly important as it underlies many of the challenges societies face - from obesity and diabetes to reproduction, population control and aging. Endocrinology covers a broad field from basic molecular and cellular communication through to clinical care and some of the most crucial public health issues. The journal, thus, welcomes outstanding contributions in any domain of endocrinology.
Frontiers in Endocrinology publishes articles on the most outstanding discoveries across a wide research spectrum of Endocrinology. The mission of Frontiers in Endocrinology is to bring all relevant Endocrinology areas together on a single platform.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
